Seoul National University Bundang Hospital (SNUBH)
Medulloblastoma treatment cost in South Korea typically depends on the surgical approach and clinic tier, with a brain MRI costing AUD $42 – AUD $140 and primary procedures like a craniotomy running from AUD $23,034 to AUD $53,048. Total expenses usually run 30–50% lower than in Australia. Patients most frequently travel to Seoul, specifically to districts housing major medical hubs like Gangnam.
Typical Medulloblastoma Treatment Costs in South Korea
Bookimed Expert Insight: Advanced neuro-oncology cases benefit from the digital safety systems at Seoul National University Bundang Hospital. Their BESTcare system actively prevents medical errors during complex brain surgeries. For patients needing multidisciplinary care, Asan Medical Centre is the largest centre in South Korea. It handles over 65,000 operations annually, which means its surgical teams manage rare medulloblastoma complications routinely. JCI-accredited facilities like Severance Hospital offer additional quality assurance for international patients.
| Republic of Korea | Thailand | Turkey | |
| Craniotomy | from AUD $23,034 | from AUD $20,940 | from AUD $9,074 |
| Chemotherapy for breast cancer | from AUD $26,803 | from AUD $4,188 | from AUD $1,675 |
| Stereotaxic radiosurgery | - | from AUD $13,960 | from AUD $6,282 |
| Radiation therapy for colorectal cancer | - | from AUD $7,678 | from AUD $9,772 |
No hidden fees – just official clinic prices. Pay at the clinic for Medulloblastoma treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Medulloblastoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Medulloblastoma treatment journey.
Professor Do Hyun Nam is a leading neurosurgeon at Samsung Medical Center, specialising in endoscopic brain tumour removal for paediatric and adult patients.
South Korean hospitals offer proton beam therapy for paediatric patients with medulloblastoma. Leading centres like Samsung Medical Center and the National Cancer Center provide pencil beam scanning. This technology treats brain tumours while sparing developing tissue. Specialists like Dr Do Hyun Nam manage these complex cases.
Bookimed Expert Insight: While many centres treat adult cancers, only a few specialise in paediatric proton therapy. Samsung Medical Center and Severance Hospital stand out by partnering with leading US paediatric institutions. This means protocols for medulloblastoma align with the highest global standards for developing brains.
Patient Consensus: Patients note proton therapy is vital for medulloblastoma. It reduces radiation to healthy tissue. Many recommend sending pathology reports to South Korea early. This confirms the diagnosis and appointment dates.
Standard care in Korea involves maximal safe surgical resection. This is followed by risk-adapted radiotherapy and intensive chemotherapy. Major Seoul centres use molecular subgrouping to tailor protocols. This approach achieves high survival rates. It relies on precise craniospinal irradiation. For high-risk cases, it also includes tandem high-dose chemotherapy with stem cell rescue.
Bookimed Expert Insight: Korea's leading hospitals are massive clinical hubs. Neurosurgeons and oncologists work in the same building. Severance Hospital alone treats 4 million patients annually. This enormous volume means Korean specialists see rare medulloblastoma subtypes weekly. These doctors often partner with top US institutions like MD Anderson. This brings global expertise to every case.
Patient Consensus: Patients note that Korean hospitals require local pathology confirmation from original slides before starting. This process is thorough. Teams remain open to providing second opinions on existing international diagnoses. Residents emphasise that large tertiary university hospitals are the standard choice. This applies to complex cancer treatment in Korea.
South Korean medical centres report a 5-year overall survival rate between 75% and 85% for standard-risk medulloblastoma cases. Specialised paediatric protocols in Seoul have achieved 5-year survival rates as high as 95.8%. Outcomes depend heavily on surgical resection success and molecular tumour subtypes.
Bookimed Expert Insight: South Korea's survival rates are bolstered by high-volume Gamma Knife centres. Seoul National University Hospital maintains a 90% success rate with this technology. This experience is vital for medulloblastoma. Specialists like Dr Do Hyun Nam manage both paediatric and adult cases. This supports continuity of care as patients transition into adulthood.
Patient Consensus: Patients emphasise finding the specific molecular subgroup, such as WNT or Group 3. This helps them understand the outlook. Korean teams often focus on aggressive therapy. This typically includes surgery followed by radiation and chemotherapy to achieve a cure.
Korean specialists treat medulloblastoma in children under 3 years using radiation-sparing protocols. This helps protect developing brains. Treatment prioritises maximal safe surgical resection followed by intensive chemotherapy. Major Seoul centres often employ tandem high-dose chemotherapy with autologous stem cell rescue. This delays or avoids craniospinal irradiation.
Bookimed Expert Insight: Many Korean neurosurgery departments handle massive volumes. This includes those at Seoul National University Hospital and Gangnam Severance Hospital. These centres perform between 1,300 and 3,800 neurosurgical interventions annually. This high frequency allows surgeons to refine techniques for delicate paediatric cases. It often results in higher success rates for complex tumour removals than lower-volume regional hospitals.
Patient Consensus: Families note that age and molecular subgroup are vital. These factors determine the choice between radiation-sparing plans and proton therapy. Parents often suggest asking specifically for proton therapy. This reduces damage to healthy brain tissue in toddlers.
South Korea has three leading neuro-oncology centres. They are Seoul National University Hospital (SNUH), Asan Medical Center, and Severance Hospital. These research-driven institutions use GammaKnife and robotic systems. They consistently appear in Newsweek’s World’s Best Hospitals list for specialised neurological and oncology care.
Bookimed Expert Insight: Major centres like Seoul National University Hospital (SNUH) are famous. However, their high volume means 30,000 international patients visit annually. For urgent medulloblastoma cases, Korea University Anam Hospital offers a distinct advantage. They provide same-day consultations, tests, and admission for new cancer patients to expedite treatment.
Patient Consensus: Patients say that Samsung Medical Center and Asan Medical Center are top-tier cancer centres. They suggest prioritising the clinic that offers the fastest expert review for urgent cases.
South Korea actively conducts clinical trials and intensive salvage protocols for relapsed medulloblastoma. Treatment focuses on high-dose chemotherapy and autologous stem cell transplantation. Major centres lead research through the Korean Society for Pediatric Neuro-Oncology (KSPNO). These include Severance Hospital and Seoul National University Hospital.
Bookimed Expert Insight: Many Australian families look for trials in the US. However, South Korean centres like Severance Hospital maintain direct research partnerships with the Children's Hospital of Philadelphia. This link allows Korean specialists to implement advanced paediatric protocols quickly. Data shows these high-volume centres treat thousands of international patients annually. They offer a sophisticated alternative for complex relapses.
Patient Consensus: Families note that relapsed cases often require trial hunting beyond standard surgery and radiation. Research shows searching for specific paediatric neuro-oncology protocols works better in the Republic of Korea. This approach is more effective than looking for general brain cancer programmes.